Loading…

Melatonin as adjunctive therapy in patients admitted to the Covid-19

Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear. Therefore, our aim was to dete...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine and surgery 2022-04, Vol.76, p.103492-103492, Article 103492
Main Authors: Karimpour-razkenari, Elahe, Naderi-Behdani, Fahimeh, Salahshoor, Ali, Heydari, Fatemeh, Alipour, Abbas, Baradari, Afshin Gholipour
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication. The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously, but its effects on covid-19, especially COVID -19 ICU, is unclear. Therefore, our aim was to determine the effects of melatonin in COVID-19 ICU patients. This is a retrospective cohort study in which the records of patients admitted to COVID -19 ICU of (XXX) during March to June 2020 were reviewed. According to inclusion criteria, patients who received 15 mg of melatonin daily were called MRG and the rest were called NMRG. Thirty-one patients were included and analyzed, of which twelve patients were in MRG. Demographic and clinical characteristics, and laboratory data were similar between two groups at ICU admission. Melatonin had no significant effect on ICU duration, CRP and ESR, also the trend of changes was in favor of melatonin. Nevertheless, melatonin significantly reduced the NLR (OR = −9.81, p = 0.003), and also declined mortality marginally (p = 0.09). Melatonin was well tolerated with no major adverse effects, moreover the thrombocytopenia occurrence was significantly lower in MRG (p = 0.005). In MRG, survival increased and mortality risk decreased, although the difference between groups wasn't significant (p = 0.37), which might be related to the small sample-size. Our study showed that melatonin is unlikely to reduce mortality among COVID19 patients and with no significant effect on disease-specific biochemical parameters. -Coronavirus has disrupted the natural order of the world since September 2019 with no specific medication.-The beneficial effects of melatonin on sepsis and viral influenza were demonstrated previously.-Our survey showed melatonin had a beneficial effect on survival and mortality risk.-As well as platelets and lymphocytes without life-threatening complications.-Melatonin was an essential adjuvant therapy in patients admitted to covid-19 ICU.
ISSN:2049-0801
2049-0801
DOI:10.1016/j.amsu.2022.103492